임상시험 트래커
추적 기업 30곳의 임상 6,982건 (국내 전체 이력 · 글로벌 진행 중). 출처: ClinicalTrials.gov
35건 표시
- 1/2상모집 중· Advanced Solid TumorsA First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer
리드: 종근당
- 1/2상모집 중· EGFR OverexpressionClinical Trial of YH32364 in Patients With Locally Advanced or Metastatic EGFR Overexpressing Solid Tumors
리드: 유한양행
- 1/2상모집 중· Tetanus-diphtheria-acellular Pertussis (Tdap)A Phase I/II Study to Evaluate the Safety and Immunogenicity of GC3111B in Healthy Adults
리드: GC녹십자
- 1/2상모집 중· Fabry DisesaseA proof-of Concept Study to Assess Safety and Tolerability of HM15421/GC1134A in Patients With Fabry Disease
리드: GC녹십자 · 협력: 한미약품
- 1/2상모집 중· Japanese Encephalitis Virus DiseaseA Study to Assess the Safety, Reactogenicity, and Immunogenicity of SK Japanese Encephalitis Messenger Ribonucleic Acid (mRNA) Vaccines (GBP560) in Healthy Adults
리드: SK바이오사이언스
- 1/2상모집 중· NSCLC (Non-small Cell Lung Cancer)A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946
리드: 유한양행
- 1/2상조기 종료· Advanced Solid TumorSafety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients
리드: SK바이오팜
- 1/2상모집 중· HER2-Positive Solid TumorClinical Trial of YH32367 in Patients With HER2 Positive Locally Advanced or Metastatic Solid Tumor
리드: 유한양행
- 1/2상상태 미확인· COVID-19 (Healthy Volunteers)Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With or Without AS03 (COVID-19)
리드: SK바이오사이언스
- 1/2상완료· COVID-19 (Healthy Volunteers)Safety and Immunogenicity Study of SARS-CoV-2 Nanoparticle Vaccine (GBP510) Adjuvanted With Aluminum Hydroxide (COVID-19)
리드: SK바이오사이언스
- 1/2상완료· Non-Alcoholic Fatty Liver DiseaseEffects of Probiotics (P. Pentosaceus, L. Lactis or L. Helveticus) in NASH
협력: 종근당
- 1/2상완료· Carcinoma, Non-Small-Cell LungA Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
협력: 유한양행
- 1/2상완료· Metastatic Colorectal CancerA Study to Assess Safety, Efficacy, Immunogenicity, PK of GC1118 With Combination Chemotherapy
리드: GC녹십자
- 1/2상완료· EGFR Gene MutationClinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC
리드: 유한양행
- 1/2상조기 종료· Acute Myeloid LeukemiaClinical Study of CWP232291 in Acute Myeloid Leukemia Patients
리드: JW중외제약
- 1/2상상태 미확인· Colorectal CancerA Phase 1/2a Study to Assess the Safety and Efficacy of CKD-516 Tab. in Combination With Irinotecan Inj.
리드: 종근당
- 1/2상완료· Recessive Dystrophic Epidermolysis BullosaSafety and Effectiveness Study of Allogeneic Umbilical Cord Blood-derived Mesenchymal Stem Cell in Patients With RDEB
협력: 대웅제약
- 1/2상상태 미확인· TetanusSafety and Immunogenicity Study of Tetanus, Diphtheria and Acellular Pertussis (Tdap) Vaccine
리드: GC녹십자
- 1/2상조기 종료· Otitis MediaA Clinical Trial of YH1177 in Patients With Otitis Media and Otorrhea
리드: 유한양행
- 1/2상완료· Functional ConstipationPhase 1/2a Trial of YH12852 in Healthy Subjects and Patients With Functional Constipation
리드: 유한양행
- 1/2상상태 미확인· Chronic Hepatitis C Virus Genotype ISafety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)
리드: 한미약품
- 1/2상상태 미확인· Unspecified Adult Solid Tumor, Protocol SpecificA Study of KX2-391 With Paclitaxel in Patients With Solid Tumors
리드: 한미약품
- 1/2상완료· HER-2 Positive Advanced Gastric CancerA Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer
리드: 한미약품
- 1/2상완료· Degenerative Disc DiseaseSafety, Tolerability and Efficacy of YH14618 in Patients With Degenerative Disc Disease
리드: 유한양행
- 1/2상완료· Non Small Cell Lung CancerPhase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients
리드: 한미약품
- 1/2상완료· Mucopolysaccharidosis IITo Evaluate the Safety and Efficacy of GC1111 (Recombinant Human Iduronate-2-sulfatase) in Hunter Syndrome Patients
리드: GC녹십자
- 1/2상완료· InfluenzaStudy to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers
리드: GC녹십자
BioPulse가 제공하는 정보는 공개된 자료를 요약·정리한 것으로, 투자 조언이나 의료 조언이 아닙니다. 임상 데이터·규제 일정·공시 내용은 반드시 원문을 직접 확인하시기 바랍니다.